Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan current therapeutic effects and perspectives for clinical use

Atherosclerosis

Volumn 81, Issue 3, 1990, Pages 233-243

  Crepaldi, G ^a   Fellin, R ^a   Calabro A ^a   Rossi, A ^a   Ventura, A ^b   Mannarino, E ^b   Senin, U ^b   Ciuffetti, G ^b   Descovich, G C ^c   Gaddi, A ^c   Rimondi, S ^c   Pozza, G ^d   Vicari, A ^d   Carandente, O ^d   Mancini, M ^e   Rubba, P ^e   Postiglione, A ^e   Strano, A ^f   Avellone, G ^f   Davi G ^f   Novo, S ^f   Pinto, A ^f   Capurso, A ^g   Resta, F ^g   Mogavero, A M ^g   Bucci, A ^h   Antonini, R ^h   Lalloni, L ^h   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Department of Organic Chemistry   (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Blood viscosity; Glycosaminoglycans; Peripheral vascular disease; Thrombosis

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN; SULODEXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTILIPEMIC AGENTS; BLOOD VISCOSITY; CHOLESTEROL; CLINICAL TRIALS; DOUBLE-BLIND METHOD; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN; GLYCOSAMINOGLYCANS; HUMAN; HYPERCHOLESTEROLEMIA, FAMILIAL; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE V; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; MALE; MIDDLE AGE; MULTICENTER STUDIES; TRIGLYCERIDES;

EID: 0025264190     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(90)90071-P     Document Type: Article

References (64)

1. Structure and metabolism of proteoglycans and glycosaminoglycans
2. Glycosaminoglycans and their binding to biological macromolecules
3. Plasma glycosaminoglycans in normal individuals of various age
4. Partial structure of the active moiety of a lipoprotein complexing proteoglycan from human aorta
5. A heparin analogue with specific action on antithrombin III
6. Effect of naturally mucopolysaccharide, 3-GS, on coagulative parameters in patients under chronic haemodialytic treatment
7. Effects of some mucopolysaccharides on activated factor X
8. An International Multicentre Trial Prevention of fatal postoperative pulmonary embolism by low doses of heparin
9. Prophylaxis against postoperative pulmonary embolism and deep vein thrombosis by low doses of heparin
10. Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction
11. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis
12. Double-blind randomized trial of ORG 10172 LMW in prevention of deep vein thrombosis in thrombotic stroke
13. Sulodexide in the treatment of peripheral arterial disease
14. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial
15. Double-blind study of the pharmacological effects of Sulodexide in patients with multiple atherosclerotic vascular disease
16. The preventive activity of an extractive glycosaminoglycan in relapses of TIA. A short term study
17. Sulodexide in the treatment of atherosclerosis: a controlled clinical trial
18. Experiences with Sulodexide in the arterial peripheral disease
19. In vivo and in vitro effect of a sulphated mucopolysaccharide on the aortic uptake of a cholesterol-rich VLDL in rabbits
20. Age-related changes in cell content (DNA) and glycosaminoglycans degrading enzymes of connective tissue and parenchymal organs of the rat caused by 6-methylprednisolone
21. Age-related changes in the content and composition of glycosaminoglycans isolated from the mouse skeletal muscle: normal and dystrophic conditions
22. Age-related changes in the kinetics of release of proteoglycans from normal rabbit cartilage explants
23. Variations in the proteoglycans of the canine intervertebral disc with ageing
24. Glycosaminoglycans in normal and atherosclerotic human coronary arteries
25. Lipoprotein acid mucopolysaccharide complexes of human atherosclerosis lesions
26. Plasma LDL accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycans composition
27. A proposed structure of chondroitin 6-sulphate proteoglycan of human normal and adjacent atherosclerotic plaque
28. Hypercholesterolemia and aortic glycosaminoglycans of rabbit fed semi-purified diets containing sucrose and lactose
29. Urinary glycosaminoglycan, sialic acid and lysosomal enzymes increase in non-albuminuric diabetic patients
30. Preliminary results of Sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre study
31. Characterization of heparin subfractions in antithrombotic glycosaminoglycans from pig mucosa
32. NIH Consensus Development Conference Statement lowering blood cholesterol to prevent heart disease
33. Classification of hyperlipidemias and hyperlipoproteinemias
34. Familial Hypercholesterolemias
35. Distribution of some risk factors for atherosclerosis in nine Italian population samples
36. Familial Hyperlipoproteinemias: age effects on lipoprotein metabolism during hypocholesterolemic diets
37. The isolation and quantitative analysis of serum lipoproteins
38. The CNR Programme of Preventive Medicine-SP4 Objective 44: noninvasive techniques for the evaluation of atherosclerotic plaque progression or regression
39. Haemorrheological effect of Sulodexide
40. Action of intravenous glucosamine-glycansulphate on lipid blood components and blood viscosity in patients with acute regional vasculopathies
41. The influence of Sulodexide on some coagulation parameters, a pharmacokinetic study
42. Modificazioni di alcuni fattori emoreologici e parietali dal Sulodexide in pazienti aterosclerotici ed iperlipidemici
43. The biosynthesis of fibrinogen: in vivo studies
44. In vitro effect of ateroid on the fibrinolytic activity in rat euglobulins
45. Effetti del Sulodexide sul sistema coagulativo-fibrinolitico e sull'attivita lipasemica nell' uomo
46. Studies of chemical and biological properties of a fraction of Sulodexide, a heparinlike glycosaminoglycan
47. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides
48. Variazioni della composizione delle lipoproteine del siero e dell'attiviO lipoproteinlipasica indotte dal glucoronilglucosaminoglicano solfato: confronto con l'eparina sodica
49. Glukoronyl-Glycansulfat in der Behandlung der Hyperlipaemie
50. Effects of the extractive heparinoid, glucoronylglucosaminglycan sulfate (3GS) on human plasma lipids
51. Clinical evaluation of Sulodexide long term treatment in atherosclerotic dyslipidemic patients
52. The use of Sulodexide in the treatment of peripheral vasculopathy accompanying metabolic disease. Controlled study in hyperlipidemic and diabetic subjects
53. Clinical investigation on efficacy of extractive glucoronoglycan sulphate in cases of hyperlipidemia
54. Effect of Sulodexide, a heparin-like compound, on VLDL-triglyceride in perfused rat liver
55. The interaction of human plasma glycosaminoglycans with plasma lipoproteins. II. Hemagglutination studies
56. AHA Consensus Panel on hypertriglyceridemia management
57. Inhibition of rat arterial smooth cell proliferation by heparin
58. Inhibition of rat arterial smooth muscle cell proliferation by haparin. In vivo studies with anticoagulant and non-anticoagulant heparins
59. Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types
60. Proteoglycans and potential mechanisms related to atherosclerosis